- Home
- BNTC vs GOSS Comparison
BNTC vs GOSS Comparison
Compare BNTC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTC
- GOSS
- Stock Information
- Founded
- BNTC 1995
- GOSS 2015
- Country
- BNTC United States
- GOSS United States
- Employees
- BNTC N/A
- GOSS N/A
- Industry
- BNTC Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- BNTC Health Care
- GOSS Health Care
- Exchange
- BNTC Nasdaq
- GOSS Nasdaq
- Market Cap
- BNTC 335.5M
- GOSS 347.8M
- IPO Year
- BNTC N/A
- GOSS 2019
- Fundamental
- Price
- BNTC $13.24
- GOSS $2.47
- Analyst Decision
- BNTC Strong Buy
- GOSS Strong Buy
- Analyst Count
- BNTC 5
- GOSS 4
- Target Price
- BNTC $26.00
- GOSS $8.50
- AVG Volume (30 Days)
- BNTC 40.8K
- GOSS 3.1M
- Earning Date
- BNTC 09-25-2025
- GOSS 08-05-2025
- Dividend Yield
- BNTC N/A
- GOSS N/A
- EPS Growth
- BNTC N/A
- GOSS N/A
- EPS
- BNTC N/A
- GOSS N/A
- Revenue
- BNTC N/A
- GOSS $40,237,000.00
- Revenue This Year
- BNTC N/A
- GOSS N/A
- Revenue Next Year
- BNTC N/A
- GOSS $30.65
- P/E Ratio
- BNTC N/A
- GOSS N/A
- Revenue Growth
- BNTC N/A
- GOSS N/A
- 52 Week Low
- BNTC $8.06
- GOSS $0.66
- 52 Week High
- BNTC $17.15
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- BNTC 59.72
- GOSS 68.08
- Support Level
- BNTC $12.57
- GOSS $2.38
- Resistance Level
- BNTC $13.33
- GOSS $2.65
- Average True Range (ATR)
- BNTC 0.60
- GOSS 0.15
- MACD
- BNTC 0.10
- GOSS 0.03
- Stochastic Oscillator
- BNTC 95.59
- GOSS 76.67
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.